The European Food Safety Authority authorizes Huvepharma’s B-ACT® to be used as a feed additive in animal nutrition.
European Union through its regulations (EU) 2017/1904 of 18th October 2017, concluded in its opinion of 18th October 2016(1) that, under the proposed conditions of use, the Bacillus licheniformis DSM 28710 (B-Act®)does not have an adverse effect on animal health, human health or the environment.
The Authority does not consider that there is a need for specific requirements of post-market monitoring. It also verified the report on the method of analysis of the feed additive in feed submitted by the Reference Laboratory set up by Regulation (EC) No 1831/2003.
The main action of B-Act® is the inhibition of Clostridium perfringens and thus the prevention of necrotic enteritis. B-Act® increases weight gain, improves FCR, prevents mortality and lowers Lesion scores under different necrotic enteritis challenges.
Theuniqueness about Bacillus licheniformis(Strain Accession Number-DSM 28710)is secreting metabolite lichnicidine,which has antimicrobial effect on gut pathogens. It is compatible with decoquinate, diclazuril, halofuginone, nicarbazine, robenidine, lasolacidA sodium, maduramicin ammonium, monesin sodium, narasin and salinomycin sodium.
Huvepharma is a global company with emphasis on fermentation technology for animal and human welfare. Huvepharma has expertise inintestinal health, coccidiostats, enzymes and respiratory health control programs.
Huvepharmahas extensive production facilities in Europe & the USA, which produce a wide range of products. Huvepharma’s technical team also provides technical services like gut lesion scoring to the poultry farming community to assess gut health of birds and respond back with effective tools in time.